Preimplantation genetic testing for aneuploidy (PGT-A) is a genetic test that can be performed on embryos produced through IVF to screen for chromosomal abnormalities.

The term 'preimplantation' is used because testing is performed on embryos during the time before they would naturally implant into the uterus (usually after day 6). PGT-A is offered as a complement to a patient’s in vitro fertilisation (IVF) treatment.

PGT-A offered by Next Biosciences aims to improve pregnancy success rates and reduce the risk of miscarriage by avoiding the transfer of embryos with the incorrect number of chromosomes.

What is a chromosomal abnormality?

Humans typically have 23 pairs of chromosomes (46 in total) within almost every cell in our body. One chromosome of each pair comes from our mother, and the other from our father. The first chromosome pairs are labelled 1-22. The last pair of these chromosomes are the sex chromosomes, which determine if you are genetically male or genetically female. Individuals who are genetically female typically have two X chromosomes, while individuals who are genetically male typically have an X and a Y chromosome.

A change in the number of chromosomes can lead to a change in development. Embryos with the incorrect number of chromosomes are unlikely to lead to a successful pregnancy, may end in a miscarriage, or may result in the birth of a child with a genetic condition. 

Embryos with the correct number of chromosomes are more likely to lead to a successful pregnancy.

What is PGT-A 1
Aneuploid